Molecular Cancer

Article	Citations
Immunotherapies in rare cancers	1166
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	700
Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early-stage NSCLC	663
Retraction Note: Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway	444
Retraction Note: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression	439
Retraction Note: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer	419
Retraction Note to: Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner	402
Editorial expression of concern: Activation of the NF-κB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma	376
Retraction Note: CircTLK1 promotes the proliferation and metastasis of renal cell carcinoma by sponging miR-136-5p	371
Retraction Note: α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway	357
Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC	350
Long noncoding RNA DLGAP1-AS2 promotes tumorigenesis and metastasis by regulating the Trim21/ELOA/LHPP axis in colorectal cancer	324
Retraction Note to: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis	310
CircRNF13 enhances IGF2BP1 phase separation-mediated ITGB1 mRNA stabilization in an m6A-dependent manner to promote oral cancer cisplatin chemoresistance	289
Radioresistance in rectal cancer: can nanoparticles turn the tide?	274
Ferroptosis and pyroptosis are connected through autophagy: a new perspective of overcoming drug resistance	243
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	236
Hijacking of the nervous system in cancer: mechanism and therapeutic targets	224
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes	222
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	216
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold	216
Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors	213
PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation	203
circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis	200
Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers	191

The senescence journey in cancer immunoediting	185
CRISPR based therapeutics: a new paradigm in cancer precision medicine	174
LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer	170
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma	165
Extracellular vesicles in tumor immunity: mechanisms and novel insights	154
N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2	153
Incidence, risk factors, and epidemiological trends of tracheal cancer: a global analysis	151
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer	145
Mapping cancer biology in space: applications and perspectives on spatial omics for oncology	142
Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial	142
SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis	140
The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers	139
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?	135
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities	132
Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer?	131
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	126
Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies	124
The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer	121
Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3–eIF3h interaction	121
Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy	120
Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma	118
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer	117
Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells	116
Clustering cancers by shared transcriptional risk reveals novel targets for cancer therapy	115
Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade	115
The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression	114
CircIL4R activates the PI3K/AKT signaling pathway via the miR-761/TRIM29/PHLPP1 axis and promotes proliferation and metastasis in colorectal cancer	111
Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p	111
lncRNA ZNRD1-AS1 promotes malignant lung cell proliferation, migration, and angiogenesis via the miR-942/TNS1 axis and is positively regulated by the m6A reader YTHDC2	111
METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis	110
The function and mechanisms of action of circular RNAs in Urologic Cancer	108
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo	106
Immunotherapy: an emerging modality to checkmate brain metastasis	105
Two circPPFIA1s negatively regulate liver metastasis of colon cancer via miR-155-5p/CDX1 and HuR/RAB36	104
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	104
Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program	102
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells	101
LINC00922 decoys SIRT3 to facilitate the metastasis of colorectal cancer through up-regulation the H3K27 crotonylation of ETS1 promoter	101
Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment	101
Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases	100
LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling	99
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis	99
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer	99
Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy	99
Therapeutic challenges in peripheral T-cell lymphoma	98
i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations	98
Extracellular vesicles remodel tumor environment for cancer immunotherapy	98
Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis	97
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia	97
Evolution of cell therapy for renal cell carcinoma	97

Clinical application and detection techniques of liquid biopsy in gastric cancer	96
Correction: Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation	95
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy	95
The DNA damage sensor ATM kinase interacts with the p53 mRNA and guides the DNA damage response pathway	95
Cuproptosis: mechanisms and links with cancers	93
Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome	93
CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinoma	91
Drug resistance in ovarian cancer: from mechanism to clinical trial	89
m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism	86
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy	85
Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application	84
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	84
Aberrant R-loop–mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis	83
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway	83
Expression of mTOR in normal and pathological conditions	83
Unraveling the key role of chromatin structure in cancer development through epigenetic landscape characterization of oral cancer	83
Exploiting autophagy balance in T and NK cells as a new strategy to implement adoptive cell therapies	82
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	82
Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles	81
LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy efficacy in non-small cell lung cancer	80
Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets	80
Circular RNAs in tumor immunity and immunotherapy	80
Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications	80
Novel humanized monoclonal antibodies against ROR1 for cancer therapy	79
Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells	78
LINC01852 inhibits the tumorigenesis and chemoresistance in colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM	78
A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology	77
A multidimensional recommendation framework for identifying biological targets to aid the diagnosis and treatment of liver metastasis in patients with colorectal cancer	77
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial	77
Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing	77
A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/β-catenin signaling pathway to promote gastric cancer progression	76
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3	76
m6A modification: recent advances, anticancer targeted drug discovery and beyond	76
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy	76
The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p	75
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer	74
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	73
DNMT1-targeting remodeling global DNA hypomethylation for enhanced tumor suppression and circumvented toxicity in oral squamous cell carcinoma	73
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	73
Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication	73
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis	72
Targeting m7G-enriched circKDM1A prevents colorectal cancer progression	72
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes	71
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer	71
Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform ‘cold’ tumors into ‘hot’ tumors	70
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer	69
CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing	69
ERK mediates interferon gamma-induced melanoma cell death	69
The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	69
A novel NF-κB regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation	68
Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6	68
An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma	67
CircMYH9 drives colorectal cancer growth by regulating serine metabolism and redox homeostasis in a p53-dependent manner	67
The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells	67
Histone citrullination: a new target for tumors	67
CircRNF220, not its linear cognate gene RNF220, regulates cell growth and is associated with relapse in pediatric acute myeloid leukemia	67
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges	66
Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions	66
A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling	64
Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine	64
Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling	64
Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers	64
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches	63
Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy	63
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition	62
A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy	61
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer	61
Lung cancer immunotherapy: progress, pitfalls, and promises	61
Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer	61
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T	60
NK cells and solid tumors: therapeutic potential and persisting obstacles	59
A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer	59
Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives	59
CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p/NUPR1/FTH1 axis	59
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer	59
The use of RNA-based treatments in the field of cancer immunotherapy	59
TGF-β signaling promotes cervical cancer metastasis via CDR1as	59
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development	58
Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC	58
Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance	58

Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial	57
Neutrophils in Cancer immunotherapy: friends or foes?	57
Correction: Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma	56
Cancer, metastasis, and the epigenome	56
Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib	55
Correction to: Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA	55
Correction: Nac1 promotes stemness and regulates myeloid‑derived cell status in triple‑negative breast cancer	55
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy	54
Correction to: LMTK3 inhibition affects microtubule Stability	54
Correction to: Circular RNA circERBB2 promotes gallbladder cancer progression by regulating PA2G4-dependent rDNA transcription	53
Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC	53
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance	53
hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma	52
Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies	52
Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer	52
Using single-cell sequencing technology to detect circulating tumor cells in solid tumors	52
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	52
Correction: Reprogramming anchorage dependency by adherent‑to‑suspension transition promotes metastatic dissemination	52
Minimally invasive approaches for the early detection of endometrial cancer	52
circRNAs shed light on cancer diagnosis and treatment	51
The University of Kansas Cancer Center (KUCC), an NCI designated comprehensive cancer center	51
Targeting the tumor stroma for cancer therapy	51
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy	50
REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial	50
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials	50
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer	50
CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth	50
Regulatory cells and the effect of cancer immunotherapy	49
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	49
Multiomics-based molecular subtyping based on the commensal microbiome predicts molecular characteristics and the therapeutic response in breast cancer	48
Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing	48
Correction to: The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs	48
CAR T cells: engineered immune cells to treat brain cancers and beyond	47
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection	47
Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression	46
m6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion	46
The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1	46
CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2	45
Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy	45
CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma	45
The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy	44
The role of m6A methylation in therapy resistance in cancer	44
Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives	44
Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells	44
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies	44
Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients	44
Emerging role of exosomes in cancer therapy: progress and challenges	43
Correction: RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy	43
Resistance mechanisms to immune checkpoint inhibitors: updated insights	43
Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity	43
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer	43
Bidirectional role of neutrophils in tumor development	43
Correction: CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer	43
The journey of CAR-T therapy in hematological malignancies	42
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy	42
The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications	42
circASAP1 induces renal clear cell carcinoma ferroptosis by binding to HNRNPC and thereby regulating GPX4	42
Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer	42
Mir-483-5p-mediated activating of IGF2/H19 enhancer up-regulates IGF2/H19 expression via chromatin loops to promote the malignant progression of hepatocellular carcinoma	41
CircZBTB44 promotes renal carcinoma progression by stabilizing HK3 mRNA structure	41
Exosomal circ_0006896 promotes AML progression via interaction with HDAC1 and restriction of antitumor immunity	41
The incorporation of acetylated LAP-TGF-β1 proteins into exosomes promotes TNBC cell dissemination in lung micro-metastasis	40
Serum small RNAs in metastatic colorectal cancer predict response to chemotherapy and characterize high-risk patients	40
Multicancer screening test based on the detection of circulating non haematological proliferating atypical cells	40
Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop	40
Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship	40
Circular RNA EIF4G3 suppresses gastric cancer progression through inhibition of β-catenin by promoting δ-catenin ubiquitin degradation and upregulating SIK1	40
Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer	40
The evolution and heterogeneity of neutrophils in cancers: origins, subsets, functions, orchestrations and clinical applications	39
Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer	39
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	39
A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma	39
Writers, readers, and erasers RNA modifications and drug resistance in cancer	39
CircTTC13 promotes sorafenib resistance in hepatocellular carcinoma through the inhibition of ferroptosis by targeting the miR-513a-5p/SLC7A11 axis	39